Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Aliskiren hemifumarate (CGP60536B) 一种可口服非肽肾素抑制剂,IC50为1.5 nM,具有抗高血压活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 355 | 现货 | ||
25 mg | ¥ 539 | 现货 | ||
50 mg | ¥ 925 | 现货 | ||
100 mg | ¥ 1,516 | 现货 | ||
500 mg | ¥ 2,950 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 570 | 现货 |
产品描述 | Aliskiren hemifumarate (CGP60536B) is an orally active nonpeptide renin inhibitor with antihypertensive activity. |
靶点活性 | Renin:1.5 nM |
体外活性 | Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site towards the hydrophobic core of renin. Oral bioavailability of Aliskiren hemifumarate is 2.4% in rats, 16% in marmosets and about 2.5% in humans. [2] |
激酶实验 | Radioligand Binding Assay: Human CB1 and CB2 stably transfect HEK 293 cells and cell membrane is purified. 0.2-8 μg of the purified membrane is incubated with 0.75 nM [3H] CP55,940 and Rimonabant in the incubation buffer (50 mM Tris-HCl, 5 mM MgCl2, 1 mM EDTA, 0.3%BSA, pH 7.4). The non-specific binding is defined in the presence of 1 μM of CP55,940. The reactions are incubated for one and a half hours at 30 °C in Multiscreen. The reactions are terminated by manifold filtration and washed four times with ice-cold wash buffer (50 mM Tris, pH 7.4, 0.25% BSA).The radioactivity bound to the filters is measured by Topcount. The IC50 is determined as the concentration of Rimonabant required to inhibit 50% of the binding of [3H] CP55,940 and calculated by non-linear regression. |
别名 | 阿利克仑半富马酸盐, CGP 60536, SPP 100, CGP60536B |
分子量 | 1219.6 |
分子式 | C30H53N3O6·1/2C4H4O4 |
CAS No. | 173334-58-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 93 mg/mL (76.3 mM)
H2O: 92 mg/mL (75.4 mM)
Ethanol: 93 mg/mL (76.3 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O / Ethanol | 1 mM | 0.8199 mL | 4.0997 mL | 8.1994 mL | 20.4985 mL |
5 mM | 0.164 mL | 0.8199 mL | 1.6399 mL | 4.0997 mL | |
10 mM | 0.082 mL | 0.41 mL | 0.8199 mL | 2.0499 mL | |
20 mM | 0.041 mL | 0.205 mL | 0.41 mL | 1.0249 mL | |
50 mM | 0.0164 mL | 0.082 mL | 0.164 mL | 0.41 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Aliskiren hemifumarate 173334-58-2 Autophagy Endocrinology/Hormones RAAS Aliskiren SPP 100 hemifumarate 阿利克仑半富马酸盐 CGP60536B hemifumarate cardiovascular diseases SPP-100 colon carcinoma cachexia cancer CGP 60536 hemifumarate Aliskiren Hemifumarate CGP 60536 Renin inhibit Hypertension C26 SPP 100 SPP100 CGP60536B CGP60536 CGP-60536 Inhibitor inhibitor